Immunosuppressive properties of CD95L-transduced "killer" hybrids created by fusing donor- and recipient-derived dendritic cells

被引:38
作者
Matsue, H
Matsue, K
Kusuhara, M
Kumamoto, T
Okumura, K
Yagita, H
Takashima, A
机构
[1] Univ Texas, SW Med Ctr, Dept Dermatol, Dallas, TX 75390 USA
[2] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan
[3] Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Tokyo, Japan
关键词
D O I
10.1182/blood.V98.12.3465
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Allogeneic immune responses, which are initiated by dendritic cells (DCs) of both donor and host origins, remain a major obstacle in organ transplantation. Presentation of intact major histocompatibility complex (MHC) molecules by allogeneic DCs and allogeneic peptides by syngeneic DCs leads to complex allogeneic immune responses. This study reports a novel strategy designed to suppress both pathways. A stable DC line XS106 (A/J mouse origin) was transfected. with CD95L cDNA and fused with splenic DCs purified from allogeneic BALB/c mice. The resulting "killer" DC-DC hybrids: (1) expressed CD95L and MHC class I and class II molecules of both AM and BALB/c origins, while maintaining otherwise characteristic surface phenotypes of mature DCs; (2) inhibited MHC class I- and class II-restricted mixed leukocyte reactions between the parental strains by triggering apoptosis of alloreactive T cells; and (3) abolished delayed-type hypersensitivity responses of A/J (and BALB/c) mice to BALB/c-associated (and A/J-associated) alloantigens when injected intravenously into A/J (and BALB/c) mice. The onset of graft-versus-host disease in (BALB/c x A/J) F1 hosts receiving A/J-derived hematopoietic cell transplantation was suppressed significantly (P <.001) by killer DC-DC hybrid treatment. These results form both technical and conceptual frameworks for clinical applications of CD95L-transduced killer hybrids created between donor DCs and recipient DCs in the prevention of allogeneic immune responses following organ transplantation. (Blood. 2001;98:3465-3472) (C) 2001 by The American Society of Hematology.
引用
收藏
页码:3465 / 3472
页数:8
相关论文
共 51 条
[11]   Direct and indirect recognition: the role of MHC antigens in graft rejection [J].
Gould, DS ;
Auchincloss, H .
IMMUNOLOGY TODAY, 1999, 20 (02) :77-82
[12]   The role of FasL-induced apoptosis in immune privilege [J].
Griffith, TS ;
Ferguson, TA .
IMMUNOLOGY TODAY, 1997, 18 (05) :240-244
[13]   Transplantation of anergic histoincompatible bone marrow allografts [J].
Guinan, EC ;
Boussiotis, VA ;
Neuberg, D ;
Brennan, LL ;
Hirano, N ;
Nadler, LM ;
Gribben, JG .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (22) :1704-1714
[14]   Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection [J].
Hale, G ;
Zhang, MJ ;
Bunjes, D ;
Prentice, HG ;
Spence, D ;
Horowitz, MM ;
Barrett, AJ ;
Waldmann, H .
BLOOD, 1998, 92 (12) :4581-4590
[15]   REDUCTION IN THE SEVERITY OF GRAFT-VERSUS-HOST DISEASE AND INCREASED SURVIVAL IN ALLOGENEIC MICE BY TREATMENT WITH MONOCLONAL-ANTIBODIES TO CELL-ADHESION ANTIGENS LFA-1-ALPHA AND MALA-2 [J].
HARNING, R ;
PELLETIER, J ;
LUBBE, K ;
TAKEI, F ;
MERLUZZI, VJ .
TRANSPLANTATION, 1991, 52 (05) :842-845
[16]   Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation [J].
Hill, GR ;
Cooke, KR ;
Teshima, T ;
Crawford, JM ;
Keith, JC ;
Brinson, YS ;
Bungard, D ;
Ferrara, JLM .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (01) :115-123
[17]  
KAMINSKI MJ, 1993, CANCER RES, V53, P4014
[18]   Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction [J].
Kang, SM ;
Schneider, DB ;
Lin, ZH ;
Hanahan, D ;
Dichek, DA ;
Stock, PG ;
Baekkeskov, S .
NATURE MEDICINE, 1997, 3 (07) :738-743
[19]   Polymorphism of murine Fas ligand that affects the biological activity [J].
Kayagaki, N ;
Yamaguchi, N ;
Nagao, F ;
Matsuo, S ;
Maeda, H ;
Okumura, K ;
Yagita, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (08) :3914-3919
[20]   Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice [J].
Lau, HT ;
Yu, M ;
Fontana, A ;
Stoeckert, CJ .
SCIENCE, 1996, 273 (5271) :109-112